{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Examined using paired t-test or Wilcoxon signed-ranks test.","groups":[{"description":"Initial cediranib maleate dosing was 45 mg (once daily) during a 28-day cycle. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Due to substantial toxicity, the starting dose was subsequently lowered to 30 mg daily.","id":"OG000","title":"Treatment (Enzyme Inhibitor Therapy)"}],"populationDescription":"This outcome was not measured/assessed for any of the study subjects.","reportingStatus":"POSTED","timeFrame":"Baseline, days 15 and 29 of course 1, and then every 28 days","title":"Changes in Laboratory Correlates","type":"SECONDARY"}